Welcome to our dedicated page for Adial Pharmaceuticals news (Ticker: ADIL), a resource for investors and traders seeking the latest updates and insights on Adial Pharmaceuticals stock.
Adial Pharmaceuticals develops clinical-stage therapies for addiction and related disorders, with its lead investigational product candidate, AD04, focused on alcohol use disorder in heavy drinking patients. News about ADIL commonly centers on AD04 clinical-development planning, FDA-related regulatory discussions, precision-medicine positioning, intellectual property filings, manufacturing and technical-transfer work, and potential commercial pathways for the program.
Company updates also cover financial results, cash runway commentary, Nasdaq listing compliance, and governance or capital-structure actions tied to its public-company status. The recurring business context is a single-segment biopharmaceutical developer advancing a genetically targeted serotonin-3 receptor antagonist approach for alcohol use disorder.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Adial Pharmaceuticals (NASDAQ: ADIL; ADILW) announced a business update for the fiscal year 2022, concluding with $4.0 million in cash and cash equivalents. Key highlights include the pivotal ONWARD™ Phase 3 trial's positive results for AD04 in reducing heavy drinking days among patients with Alcohol Use Disorder. The company is pursuing regulatory approvals, having secured meetings with the U.S. FDA and European agencies. Adial also closed a $0.75 million share offering and engaged The Keswick Group to enhance partnership activities. The company reported a reduced net loss of $12.7 million for the year, down from $19.4 million in 2021.
Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) announced the engagement of The Keswick Group, LLC, led by Tony Goodman, to enhance its partnering efforts. This strategic move follows recent analysis of the ONWARD™ data, which highlighted significant results for the AD04 treatment in reducing heavy drinking days among specific genotypes. With promising outcomes from the Phase 3 clinical trial, Adial aims to secure strategic partnerships to expedite AD04's market entry, targeting both the U.S. and European regulatory environments. The company focuses on addiction therapies, with AD04 also positioned for potential treatment of opioid use disorder and other addictions.